Login
Companies $DNTH
$89.20 -$0.35 (0.39%) After hours
Dianthus Therapeutics, Inc. logo

Dianthus Therapeutics, Inc.

dianthustx.com

What Do They Do?

Develops antibody and fusion-protein drug candidates for people with severe autoimmune diseases.

How Do They Make Money?

The company licenses antibody rights to partners for research, development and commercialization in Greater China. License terms include upfront payments, cost reimbursements and development milestones, plus royalties on licensed products’ net sales.

FY2025 revenue

Who Are Their Customers?

The company licenses drug candidates to other companies: Tenacia holds the Greater China license for claseprubart, and Leads holds an exclusive license for DNTH212.

Do Revenues Turn Into Profits?

No. It lost $162.3M in FY2025.

Operating income, FY2025
−8739% of revenue
▼ −75% (Loss) vs FY2024 (−$101.9M, −1634%)
Net income, FY2025
−7973% of revenue
▼ −91% (Loss) vs FY2024 (−$85M, −1363%)
Free cash flow, FY2025
−6349% of revenue
▼ −65% (Loss) vs FY2024 (−$78.3M, −1256%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▼ −27% (Loss)
vs −$36.8M in Q3 FY2025

From transplant to autoimmune therapies The older report centered on candidates for stem-cell conditioning and mobilization; the latest report centers on drug candidates for severe autoimmune diseases.

Who Do They Compete With?

Competes with AstraZeneca, argenx, UCB, Johnson and Johnson, Amgen, Pfizer, CSL Behring, Grifols Therapeutics, Sanofi, and Takeda

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support